A Safe, Orally Administered Agent for Dengue

一种安全的口服登革热药物

• 批准号: nhmrc : 1117470
• 负责人: Dr Kylie Wagstaff
• 金额: $ 58.51万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/safe-orally-administered-agent-dengue/946219
• 关键词: Safe; Orally; Administered; Agent; Dengue

Dengue virus is the most important mosquito-borne viral disease, with 2/3 of the world's population at risk. There is currently no treatment available for dengue. Our proposal aims to progress a safe and effective new treatment (4-HPR) against Dengue towards the clinic, generating all the required pharmacokinetic and pre-clinical animal data necessary to progress to a future clinical trial in humans. We will also investigate the use of 4-HPR as a dengue preventative.

登革热病毒是最重要的蚊媒病毒性疾病，世界上 2/3 的人口面临风险。目前尚无针对登革热的治疗方法。我们的提案旨在将一种安全有效的登革热新疗法 (4-HPR) 推向临床，生成未来进行人类临床试验所需的所有药代动力学和临床前动物数据。我们还将研究 4-HPR 作为登革热预防剂的用途。